It's official. Our little poll is closed. 18 days, 14 votes. That's pretty sad. But from the limited and not statistically significant data, I am able to draw a false conclusion that the public feels that a Sherpa is worth 10k/yr.
How's that for profit margin? Perhaps the readers who felt empowered to vote are geneticists and counselors, therefore obviously biasing the data. But what really is a Sherpa worth? Our Sherpas atHelix Healthare worth that much, but cost much less.
I was asked today by an investor "Where do you see personalized medicine headed in the next five years" I answered " It depends" Over the weekend I will list my scenarios and go over what I think the outcomes might be in different scenarios, so stay tuned. One of those big scenarios depends on how the data comes out.
A few colleagues over atCoriellare looking to create some of that data. In a collaborative effort called theDelaware Valley Personalized Medicine Projectthey hope to give us a glimpse into how this revolution may evolve. Thanks to my wonderful OraGene rep Melanie for this info. This is precisely the type of studies that need to be done to guide personalized medicine. Marker studies are cute. Outcomes studies have teeth!
Lastly, do you remember when I said that we still have alot of convincing to do? Thispostat Medical News Today is concerning. Funny, in Australia they refuse cancer risk assessments, but remarkably theDTC companytesting for athletic ability is doing just fine. It truly is funny where people place their priorities.
The Sherpa Says: As I talk with more and more investors it is getting clearer, maybe the money is not in Personalized Medicine. That's why Australian healthclubs are pimping ACTN3 testing.